Notice: This company has been marked as potentially delisted and may not be actively trading. Bellerophon Therapeutics (BLPH) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisDividendInsider TradesSustainabilityTrendsBuy This Stock Bellerophon Therapeutics (NASDAQ:BLPH) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.20%Number OfInsiders Buying(Last 3 Years)0Number OfInsiders Selling(Last 3 Years)3Amount OfInsider Selling(Last 3 Years)$5.61 M Get BLPH Insider Trade Alerts Want to know when executives and insiders are buying or selling Bellerophon Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BLPH Insider Buying and Selling by Quarter Remove Ads Bellerophon Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/13/2023Puissance Capital Management LMajor ShareholderSell1,076,841$0.10$107,684.10 6/7/2023Life Science Opportu PuissanceMajor ShareholderSell134,421$0.83$111,569.43 5/18/2023Bobae KimVPSell9,455$10.00$94,550.00 5/18/2023Life Science Opportu PuissanceMajor ShareholderSell560,000$9.46$5,297,600.00 (Data available from 1/1/2013 forward) BLPH Insider Trading Activity - Frequently Asked Questions Who is on Bellerophon Therapeutics's Insider Roster? The list of insiders at Bellerophon Therapeutics includes Bobae Kim, Life Science Opportu Puissance, and Puissance Capital Management L. Learn more on insiders at BLPH. What percentage of Bellerophon Therapeutics stock is owned by insiders? 5.20% of Bellerophon Therapeutics stock is owned by insiders. Learn more on BLPH's insider holdings. Which Bellerophon Therapeutics insiders have been selling company stock? The following insiders have sold BLPH shares in the last 24 months: Bobae Kim ($94,550.00), Life Science Opportu Puissance ($5,409,169.43), and Puissance Capital Management L ($107,684.10). How much insider selling is happening at Bellerophon Therapeutics? Insiders have sold a total of 1,780,717 Bellerophon Therapeutics shares in the last 24 months for a total of $5,611,403.53 sold. Bellerophon Therapeutics Key ExecutivesMr. Craig R. Jalbert CIRA (Age 62)President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director More Insider Trading Tools from MarketBeat Related Companies TransCode Therapeutics Insider Trades Aditxt Insider Trades Sorrento Therapeutics Insider Trades TFF Pharmaceuticals Insider Trades TC Biopharm Insider Trades Hepion Pharmaceuticals Insider Trades Smart for Life Insider Trades Evelo Biosciences Insider Trades Comera Life Sciences Insider Trades Genocea Biosciences Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles NVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It Matters This page (NASDAQ:BLPH) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellerophon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
